Cargando…
Circulating tumor cells in non-metastatic triple-negative breast cancer
Circulating tumor cells (CTCs) can be identified in approximately 25 % of stage I-III breast cancer patients; CTCs presence is a predictor of poor outcome in metastatic breast cancer, but little is known regarding the prognostic significance of CTCs in non-metastatic triple-negative breast cancer (T...
Autores principales: | Karhade, Mandar, Hall, Carolyn, Mishra, Priyankana, Anderson, Amber, Kuerer, Henry, Bedrosian, Isabelle, Krishnamurthy, Savitri, Lucci, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149877/ https://www.ncbi.nlm.nih.gov/pubmed/25164970 http://dx.doi.org/10.1007/s10549-014-3103-7 |
Ejemplares similares
-
Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer
por: Krishnamurthy, Savitri, et al.
Publicado: (2013) -
Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
por: Park, Jihyun, et al.
Publicado: (2021) -
Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse
por: Siddappa, Chidananda M., et al.
Publicado: (2019) -
Endocan as a prognostic biomarker of triple-negative breast cancer
por: Sagara, Atsunobu, et al.
Publicado: (2016) -
Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer
por: Bhardwaj, Anjana, et al.
Publicado: (2021)